Do ACEis or ARBs amplify SARS‐CoV‐2 pathogenicity and aggravate the clinical course of COVID‐19? After ACE2 was recognized as the SARS‐CoV‐2 receptor,14, 29 speculations emerged about potentially negative consequences of ACEi or ARB therapy in COVID‐19 patients. The gene discussed is ACE2; the disease is COVID-19.